Being as Normal as Possible: How Young People Ages 16–25 Years Evaluate the Risks and Benefits of Treatment for Inflammatory Arthritis

Abstract

ObjectiveTo explore how young people (ages 16–25 years) with inflammatory arthritis evaluate the risks and benefits of treatment, particularly treatment with biologic therapies.MethodsThis qualitative study involved in‐depth interviews (n = 44) with young people, trusted others (e.g., parents), and health professionals; audio‐recordings (n = 4) of biologic therapy–related consultations; and focus groups (n = 4). Analysis used techniques from grounded theory (open and focused coding, constant comparison, memoing, and mapping).ResultsYoung people aspired to live what they perceived as a “normal” life. They saw treatment as presenting both an opportunity for and a threat to achieving this. Treatment changes were therefore subject to complex and ongoing evaluation, covering administration, associated restrictions, anticipated effects, and side effects. Information sources included expert opinion (of professionals and other patients) and personal experience. Previous treatments provided important reference points. Faced with uncertain outcomes, young people made provisional decisions. Both trusted others and health professionals expressed concern that young people were too focused on short‐term outcomes.ConclusionYoung people value treatment that helps them to live a “normal” life. There is more to this than controlling disease. The emotional, social, and vocational consequences of treatment can be profound and lasting: opportunities to discuss the effects of treatment should be provided early and regularly. While making every effort to ensure understanding of the long‐term clinical consequences of taking or not taking medication, the wider impact of treatment should not be dismissed. Only through understanding young people's values, preferences, and concerns can a sustainable balance between disease control and treatment burden be achieved.

The Dilemma of Hemispherectomy for Rasmussen's Encephalitis in a Neurologically Intact Child

“…56,57 While clinical outcomes are meaningful indicators, they are not all that matter to youth. 58 Overall, in children and adolescents with epilepsy, quality of life is strongly related to their mental health, peer, and parental support, and sense of independence exhibit direct associations with health-related quality of life (HRQOL). 59,60 Mood difficulties and side effects of antiseizure medications have been reported to have a negative impact on HRQOL.…”

Healthcare transition in pediatric liver transplantation: The perspectives of pediatric and adult healthcare professionals

“…25,26 Understanding barriers to adherence from the perspective of the young person is imperative for all professionals caring for this age group 27,28 In a rheumatology study of decision-making regarding biologic therapies for arthritis, young adults expressed the need for professionals to address the wider psychosocial impact of medication regimens and not just consider them in the context of disease control and the consequences of non-adherence. 29 Approaching adherence in a developmentally appropriate manner is imperative for success and yet is not always acknowledged by HCPs. 30 Furthermore, communication strategies such as motivational interviewing which address ambivalence and emphasize self-responsibility in changing one's behavior have potential within this age group and are worthy of further study.…”

Impact of Rheumatic Disease on Social Development in Adolescents and Young Adults

“…Social functioning has been ranked as a top area impacted by RMD in those aged [16][17][18][19][20][21][22][23][24][25], with this effect on their lives more important than pain/stiffness and functional impairments (8). Table 1 shows the range of social impacts due to RMD, meaning opportunities available for healthy peers can be missed in AYA.…”

“…Conversely, some AYA report being able to use their condition or medications as a convenient excuse not to participate in behaviours they don't want to (23), with peer pressure lessened when the adverse effects were explained to peers. Treatment can be seen as both an opportunity for living a 'normal' life but also a threat to achieving this (24).…”